Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study of rivaroxaban monotherapy after PCI in patients with atrial fibrillation
NL-OMON59688Phase 4Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rivaroxaban in Atrial fibrillation (AFib), atrial flutter (AFL) and coronary arteriosclerosis, sponsored by Amsterdam University Medical Center. Primary endpoints: Primary ischemic endpoint and Primary bleeding endpoint. Started Aug 2024; status: active, not recruiting.
02
Drugs
rivaroxaban
03
Conditions
Atrial fibrillation (AFib)atrial flutter (AFL)coronary arteriosclerosis
Beyond the preview
Go deeper on NL-OMON59688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59688.